All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Not difficult at all
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with myelofibrosis (MF)?
How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?
In this video, Mascarenhas discusses the analysis from the PERSIST-2 trial (NCT02055781), a randomized phase III study that investigated the safety and efficacy of oral pacritinib compared to the best available therapy to treat MF with thrombocytopenia.
PERSIST trials: Pooled analysis of pacritinib in patients with MF and severe thrombocytopenia
Severe thrombocytopenia, defined as platelet counts of <50 × 109/L, is a recognized adverse prognostic factor in patients with myelofibrosis (MF). This...
New drug application (NDA) for accelerated FDA approval to be submitted for pacritinib in treating myelofibrosis with severe thrombocytopenia
The U.S Food and Drug Administration (FDA) has agreed to a new drug application (NDA) submission which may...
Subscribe to get the best content related to MPN delivered to your inbox